PSEG ANNOUNCES THIRD QUARTER 2026 RESULTS

PSEG reported third-quarter 2026 non-GAAP operating earnings of $1.15 per share, up from $1.13 a year earlier, while GAAP net income fell to $0.76 per share from $1.24. Nine-month operating earnings rose to $3.56 per share from $3.33, and the company reaffirmed full-year 2026 guidance of $4.28–$4.40 per share. PSEG cited utility investment and nuclear generation performance, partly offset by higher depreciation and interest costs; its $24 billion–$28 billion five-year capital plan is expected to be funded without issuing new equity or selling assets.

Analysis

The headline GAAP decline is a poor read-through to run-rate performance: most of the gap versus operating earnings is mark-to-market and nuclear-trust volatility. But the adjustment cuts both ways—MTM positions tied to forward delivery months can foreshadow realized economics, so the non-GAAP measure should not be treated as cash-earnings certainty. The cleaner signal is modest utility-led growth, not an acceleration: PSE&G investment returns are being partly absorbed by depreciation and interest before costs enter rates. That creates a regulatory-lag risk just as the multi-year capital plan pushes debt higher; the claim of no equity issuance is supportive, but increases sensitivity to rates, credit spreads, and timely cost recovery.

Near term, reaffirmed guidance and steady operating earnings limit the case for a negative reaction to GAAP EPS. Over 1–3 months, focus on the call and New Jersey regulatory decisions for evidence that investment translates into recoverable rate base. Over 6–18 months, reliable nuclear output and regional power-price strength could support the generation contribution, while outage, fuel, and policy risks remain asymmetric. Contrarian point: the result is neither a major beat signal nor proof that the growth target is secured; the quarter’s adjusted earnings barely advanced. Without valuation and consensus data, there is no strong release-driven directional edge.

Key Decisions for Investors

• Do not trade the GAAP EPS decline in isolation. Keep PEG exposure neutral on this release; reassess after the conference call rather than chasing the reaffirmation.
• Watch New Jersey regulatory recovery and PSE&G’s depreciation/interest burden. Delayed approvals or continued cost growth ahead of rates would weaken the 6–8% long-term earnings-growth thesis.
• Track debt funding and credit spreads against the capital plan. Rising financing costs or a move away from the no-equity stance would challenge the shareholder-return case.
• Treat nuclear generation and power-price upside as conditional, not as a new base-case earnings estimate. Revisit if generation reliability, realized prices, or forward-position economics deteriorate; a guidance reduction would falsify the stable-growth thesis.